Peptide services/genscript/deniger
Ended Purchase Order Awarded Last action
- Contract number
- HHSN261201700521P
- Awardee
-
Genscript USA Inc. UEI KVLBRRAQ6UX1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $8,354
Award facts
- Contract value 100% obligated
- $8,353.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Piscataway, NJ 08854, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a purchase order to Genscript USA Inc. for peptide services on August 17, 2017, with a ceiling value of $8,353.96 and an ultimate completion date of September 30, 2017. Work is performed in Piscataway, New Jersey. The order is a firm fixed price purchase order with no set-aside.
Quick answers
Who was awarded contract HHSN261201700521P?
HHSN261201700521P was awarded to Genscript USA Inc. by National Cancer Institute (National Institutes of Health) on August 17, 2017.
How much is contract HHSN261201700521P worth?
The government has obligated $8,354 on HHSN261201700521P.
Was contract HHSN261201700521P competed?
The extent of competition for HHSN261201700521P was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award